Yasuhiro, Tomoko <br/><br/>
Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.  [electronic resource] 

 -  Leukemia & lymphoma  03 2017 
 - 699-707 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.1080/10428194.2016.1201567  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Agammaglobulinaemia Tyrosine Kinase<br/>Animals<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Cell Line, Tumor<br/>Cytotoxicity, Immunologic--drug effects<br/>Disease Models, Animal<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Imidazoles--administration & dosage<br/>Killer Cells, Natural--drug effects<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Mice<br/>Neoplasm Staging<br/>Protein Kinase Inhibitors--pharmacology<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Pyrimidines--administration & dosage<br/>Rituximab--administration & dosage<br/>Treatment Outcome<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays